Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 neoadjuvant and adjuvant therapy in resectable primary liver cancer
ChiCTR2000033396Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 1-year progression-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000033396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033396.